Effect of Aspirin Dose on Mortality and Cardiovascular Events in People with Diabetes: A Meta-Analysis

[1] Buse JB(2008)Vascular protection in people with diabetes Can J Diabetes 32 S102-S106

[2] Ginsberg HN(2007)Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 30 162-172

[3] Bakris GL(2007)Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 88-136

[4] Ryden L(1994)Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Antiplatelet Trialists' Collaboration. BMJ 308 81-106

[5] Standl E(1989)Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group N Engl J Med 321 129-135

[6] Bartnik M(1998)Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial Lancet 351 1755-1762

[7] Hansson L(2003)Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) Diabetes Care 26 3264-3272

[8] Zanchetti A(2001)Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 285 2486-2497

[9] Carruthers SG(2008)The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease JAMA 300 2134-2141

[10] Sacco M(2008)Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study BMJ 337 a1840-1149

[1] Buse JB(2008)Vascular protection in people with diabetes Can J Diabetes 32 S102-S106

[2] Ginsberg HN(2007)Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 30 162-172

[3] Bakris GL(2007)Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 88-136

[4] Ryden L(1994)Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Antiplatelet Trialists' Collaboration. BMJ 308 81-106

[5] Standl E(1989)Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group N Engl J Med 321 129-135

[6] Bartnik M(1998)Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial Lancet 351 1755-1762

[7] Hansson L(2003)Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) Diabetes Care 26 3264-3272

[8] Zanchetti A(2001)Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 285 2486-2497

[9] Carruthers SG(2008)The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease JAMA 300 2134-2141

[10] Sacco M(2008)Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study BMJ 337 a1840-1149